There is current FDA approval for TAZ in epithelioid sarcoma, which exhibits PRC2 hyperactivation resulting from SWI/SNF complex mutations, and follicular lymphoma, characterized by EZH2 gain-of-function mutations (8,9). The gene discussed is EZH2; the disease is epithelioid sarcoma.